Stimulant medication and symptom interrelations in children, adolescents and adults with attention-deficit/hyperactivity disorder
Zarah van der Pal,Hilde M. Geurts,Jonas M. B. Haslbeck,Alex van Keeken,Anne Marijn Bruijn,Linda Douw,Daan van Rooij,Barbara Franke,Jan Buitelaar,Nanda Lambregts-Rommelse,Catharina Hartman,Jaap Oosterlaan,Marjolein Luman,Liesbeth Reneman,Pieter J. Hoekstra,Tessa F. Blanken,Anouk Schrantee
DOI: https://doi.org/10.1007/s00787-024-02610-8
2024-11-13
European Child & Adolescent Psychiatry
Abstract:Stimulant medication is effective in alleviating overall symptom severity of attention-deficit/hyperactivity disorder (ADHD), yet interindividual variability in treatment response and tolerability still exists. While network analysis has identified differences in ADHD symptom relations, the impact of stimulant medication remains unexplored. Increased understanding of this association could provide valuable insights for optimizing treatment approaches for individuals with ADHD. In this study, we compared and characterized ADHD symptom networks (including 18 ADHD symptoms) between stimulant-treated ( n = 348) and untreated ( n = 70) individuals with ADHD and non-ADHD controls (NACs; n = 444). Moreover, we compared symptom networks between subgroups defined by their stimulant treatment trajectory (early-and-intense use, late-and-moderate use). Stimulant-treated individuals with ADHD showed stronger associations between symptoms, compared with untreated individuals with ADHD and NACs. We found no differences in symptom networks between the stimulant treatment trajectory subgroups. Prospective longitudinal studies are needed to disentangle whether the identified differences stem from treatment or pre-existing factors.
pediatrics,psychiatry,psychology, developmental